GSK has described its full-year results as "solid" as its total sales jumped by 4% year-on-year to £32.7bn in 2025.

The pharmaceutical giant stated that its speciality medicines increased by 17% to £13.5bn, while its vaccines sales jumped by 2% to £9.2bn.

Its operating profit rose by 97% in the year to 31 December to £7.93bn, while its total earnings per share jumped by over 100% to £1.41.

GSK said the performance was driven by lower significant legal expenses, lower climate change levy charges and higher other operating income, partly offset by intangible asset impairments.

It also stated that the 11% increase in its core operating profit reflects speciality medicines and vaccines growth, higher royalty income and disciplined increased investment in R&D portfolio progression.

Chief executive officer at GSK, Luke Miels, said: "GSK delivered another strong performance in 2025, driven mainly by Specialty Medicines, with double-digit sales growth in respiratory, immunology and inflammation (RI&I), oncology and HIV. Good R&D progress also continued, with five major product approvals achieved and several acquisitions and new partnerships completed to strengthen the pipeline further in oncology and RI&I.

"We expect this positive momentum to continue in 2026, which will be a key year of execution and operational delivery with strong focus on commercial launches and accelerating R&D."

GSK has posted a dividend of 18p in the fourth quarter, with a 70p dividend expected to be posted in the 2026 financial year.

To date, it has executed £1.4bn as part of its £1bn share buyback programme announced in 2024.

In 2026, GSK expects turnover growth of between 3% to 5%, while its core operating profit growth is set to increase by between 7% and 9%.

By 2031, the pharmaceutical firm has forecast more than £40bn in sales by 2031.

Following the publication of its full-year results, GSK’s share price increased by over 4%.

Investment director at AJ Bell, Russ Mould, said that the first set of results under Miels may not have "made a splash" but this may not be a bad thing.

He concluded: "The numbers are solid enough – sales rising and returns to shareholders continuing at pace even if earnings were a touch off expectations. Plus, there were no alarms on the outlook as GSK stuck with 2026 guidance.

"This low-key start gives Miels space to chart out a course through what could be some choppy waters ahead as GSK faces the task of delivering commercially successful new drugs to make up for impending patent expiries, all while delivering on demanding growth targets."

---